Comparison between the effects of amlodipine and lisinopril on proteinuria in nondiabetic renal failure a double-blind, randomized prospective study

American Journal of Hypertension

Volumn 11, Issue 9, 1998, Pages 1074-1079

  Janssen, J J W M ^a   Gans, R O B ^a   Van Der Meulen, J ^b   Pijpers, R ^a   Ter Wee, P M ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Merwede Ziekenhuis   (Netherlands)

Author keywords

Angiotensin converting enzyme inhibitor; Dihydropyridine calcium antagonist; Nondiabetic renal failure; Proteinuria

Indexed keywords

AMLODIPINE; CALCIUM CHANNEL BLOCKING AGENT; DIHYDROPYRIDINE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LISINOPRIL;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DEVICE; DOUBLE BLIND PROCEDURE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERTENSION; KIDNEY BLOOD FLOW; KIDNEY DISEASE; KIDNEY FAILURE; MALE; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE;

ADOLESCENT; ADULT; AGED; AMLODIPINE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; KIDNEY FAILURE; LISINOPRIL; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROTEINURIA;

EID: 0032167737     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0895-7061(98)00129-0     Document Type: Article

References (25)

1. 1. Dworkin LD, Grosser M, Feiner HD, et al: The renal vascular effects of antihypertensive therapy in uninephrectomized spontaneously hypertensive rats. Kidney Int 1989;35:790-798.
2. 2. Anderson S, Meyer TW, Rennke HG, et al: Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass. J Clin Invest 1985;1985: 612-619.
3. 3. Ter Wee PM, Epstein M: Angiotensin-converting enzyme inhibitors and progression of nondiabetic chronic renal disease. Arch Intern Med 1993;153:1749-1759.
4. 4. Epstein M: Calcium antagonists and renal protection. Arch Intern Med 1992;152:1573-1584.
5. 5. Hunt LP, Short CD, Mallick NP: Prognostic indicators in patients presenting with the nephrotic syndrome. Kidney Int 1988;34:382-384.
6. 6. Weidmann P, Schneider M, Bohlen L: Therapeutic efficacy of different antihypertensive drugs in human diabetic nephropathy - an updated metaanalysis. Nephrol Dial Transplant 1995;10:39-45.
7. 7. Ikeda T, Nakayama D, Gomi T, et al: Captopril, an angiotensin 1-converting enzyme inhibitor, decreases proteinuria in hypertensive patients with renal diseases. Nephron 1989;52:72-75.
8. 8. Kloke HJ, Wetzels JFM, van Hamersvelt HW, et al: Effects of nitrendipine and cilazapril or renal hemodynamics and albuminuria in hypertensive patients with chronic renal failure. J Cardiovasc Pharmacol 1990;16: 924-930.
9. 9. Okamura M, Kanayama Y, Negoro N, et al: Long-term effects of calcium antagonists and angiotensin-converting enzyme inhibitors in patients with chronic renal failure of IgA nephropathy. Contrib Nephrol 1991;90: 161-165.
10. 10. Piccoli A, Favaro E, Piva M, et al: The progression rate of chronic renal failure with hypertension and proteinuria can be slowed by treatment with angiotensin converting enzyme inhibitors. Curr Ther Res 1993;53:309-315.
11. 11. Bianchi S, Bigazzi R, Baldari G, et al: Long-term effects of enalapril and nicardipine on urinary albumin excretion in patients with chronic renal insufficiency: a 1-year follow-up. Am J Nephrol 1991;11:131-137.
12. 12. Zuchelli P, Zuccala A, Borghi M, et al: Long-term comparison between captopril and nifedipine in the progression of renal insufficiency. Kidney Int 1992;42:452-458.
13. 13. Heeg JE, de Jong PE, van der Hem GK, et al: Reduction of proteinuria by angiotensin converting enzyme inhibition. Kidney Int 1987;32:78-83.
14. 14. Donker AJM, van der Hem GK, Sluiter WJ, et al: A radioisotope method for simultaneous determination of the glomerular filtration rate and the effective renal plasma flow. Neth J Med 1977;20:97-103.
15. 15. Heeg JE, de Jong PE, van der Hem GK, et al: Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril. Kidney Int 1989;36:272-279.
16. 16. Morelli E, Loon N, Meyer T, et al: Effects of converting enzyme inhibition on barrier function in diabetic glomerulopathy. Diabetes 1990;39:76-82.
17. 17. Gansevoort RT, Sluiter WJ, Hemmelder MH, et al: Antiproteinuric effect of blood-pressure-lowering agents: a meta-analysis of comparative trials. Nephrol Dial Transplant 1995;10:1963-1974.
18. 18. August P, Lenz T, Laragh JH: Comparative renal hemodynamic effects of lisinopril, verapamil, and amlodipine in patients with chronic renal failure. Am J Hypertens 1993;6:148S-154S.
19. 19. Bakris GL, Griffin KA, Picken MM, et al: Combined effects of an angiotensin converting enzyme inhibitor and a calcium antagonist on renal injury. J Hypertens 1997;15:1181-1185.
20. 20. Pelayo JC, Harris DC, Shanley PF, et al: Glomerular hemodynamic adaptation in remnant nephron: effects of verapamil. Am J Physiol 1988;254:F425-F431.
21. 21. Bakris GL: Effects of diltiazem or lisinopril on massive proteinuria associated with diabetes mellitus. Ann Intern Med 1990;112:707-708.
22. 22. Tarif N, Bakris GL: Preservation of renal function: the spectrum of effects by calcium-channel blockers. Nephrol Dial Transplant 1997;12:2244-2250.
23. 23. Conger JD, Falk SA: KCl and angiotensin responses in isolated rat arterioles: effects of diltiazem and low-calcium medium. Am J Physiol 1993;264:F134-F140.
24. 24. Bakris GL, Copley JB, Vicknair N, et al: Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int 1996;50:1641-1650.
25. 25. Bakris GL, Mangrum A, Copley JB, et al: Effect of calcium channel or beta-blockade on the progression of diabetic nephropathy in African Americans. Hypertension 1997;29:744-750.